Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Longboard Pharmaceuticals logo — We Are Committed To Transforming the Lives of Patients With...

Longboard Pharmaceuticals

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.

Founded 2020 United States La Jolla, United States 81 employees Post-IPO Equity Total: $79.00M Biotechnology, Health Care +1

General Information

Company Name Longboard Pharmaceuticals
Founded Year 2020
Location United States La Jolla, United States
Founders / Decision Makers
Team member Team member Team member
Employees 81
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Longboard Pharmaceuticals. To contact Longboard Pharmaceuticals, visit longboardpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Longboard Pharmaceuticals compare?

A PDF of Longboard Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Longboard Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a mission to revolutionize the lives of patients affected by neurological and rare diseases. The company is dedicated to developing groundbreaking medications for neurological conditions by focusing on a portfolio of centrally acting product candidates. Longboard's small molecule product candidates are the result of over 20 years of GPCR research, emphasizing its commitment to innovation and scientific advancement. One of the key product candidates, LP352, is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist. Longboard is pursuing its development for the potential treatment of seizures associated with a diverse range of developmental and epileptic encephalopathies, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes. Additionally, the company is evaluating LP659, a centrally acting modulator for sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5, for the potential treatment of multiple neurological diseases. Furthermore, LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, is being developed for the potential treatment of central nervous system (CNS) diseases and disorders. Founded in 2020 and headquartered in the United States, Longboard Pharmaceuticals has recently attracted Post-IPO Equity investment at 02 January 2024, marking a significant milestone in its growth. This investment speaks to the company's potential and the confidence of its investors in the impact it can make in the biotechnology, healthcare, and pharmaceutical sectors.

Business keywords: biopharmaceutical company, clinical-stage, neurological diseases, G protein-coupled receptors, small molecule product candidates, 5-hydroxytryptamine 2C (5-HT2C) receptor, epileptic encephalopathies, sphingosine-1-phosphate (S1P) receptor, multiple neurological diseases, cannabinoid type 2 receptor (CB2), central nervous system (CNS), drug development, clinical trials, neurological research, translational medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
02 Jan 2024
Post IPO Equity $23.00M -
07 Feb 2023
Series A $56.00M 5
HBM Healthcare Investments T. Rowe Price Highline Capital
HBM Healthcare Investments, T. Rowe Price +3
28 Oct 2020

Longboard Pharmaceuticals Alternatives & Competitors

View All Alternatives
Longboard Pharmaceuticals vs
Vistagen
Vistagen United States

Changing the trajectory of mental health care – One Mind at a Time

Post-IPO Equity
58 employees
Biotechnology, Pharmaceutical
Compare Longboard Pharmaceuticals vs Vistagen
Longboard Pharmaceuticals vs
Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. United States

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developin...

Post-IPO Equity
10 employees
Biotechnology, Health Care
Compare Longboard Pharmaceuticals vs Cascadian Therapeutics, Inc.
Longboard Pharmaceuticals vs
Omeros Corporation
Omeros Corporation United States

Let science lead the way

Grant
234 employees
Biotechnology, Health Care
View all alternatives

FAQ About Longboard Pharmaceuticals

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.
Longboard Pharmaceuticals was founded in 2020.
Longboard Pharmaceuticals is headquartered in La Jolla, United States.
Longboard Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical company, clinical-stage, neurological diseases and G protein-coupled receptors.
Longboard Pharmaceuticals has approximately 81 employees.
Longboard Pharmaceuticals has completed 3 funding rounds, raising a total of $79.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Longboard Pharmaceuticals include Vistagen, Cascadian Therapeutics, Inc., Omeros Corporation, Praxis Precision Medicines, Inc., ORIC Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Longboard Pharmaceuticals and Vistagen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Longboard Pharmaceuticals, https://bouncewatch.com/company/longboard-pharmaceuticals, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout